Navigation Links
PRA International Adds Dr. Susan Stansfield as Executive Vice President

RESTON, Va., Sept. 5 /PRNewswire-FirstCall/ -- PRA International (Nasdaq: PRAI), a leading clinical research organization, today announced the appointment of Dr. Susan C. Stansfield as Executive Vice President, with responsibility for Product Registration activities in Europe, Africa and Asia-Pacific. David Dockhorn, Executive Vice President, will continue to have responsibility for Product Registration activities for the Americas.

"We are very pleased to continue the process of strengthening our management team with the addition of Dr. Susan Stansfield," said Terrance J. Bieker, chief executive officer of PRA International. "The appointment of an executive dedicated to Product Registration activities in Europe, Africa and Asia-Pacific reflects the growing scale of our international operations and the additional opportunities we have to continue growing this part of our business. Dr. Stansfield has built an exceptional track record for managing world-class clinical research organizations and delivering results that increase repeat business and attract new relationships. Dr. Stansfield shares the client-centric focus that is a core value of PRA, and we believe she is well suited to take our international operations to the next level."

Dr. Stansfield has more than 20 years of experience in the clinical research industry. She joins PRA International from Pharmaceutical Product Development, Inc. (PPD), where she most recently served as Senior Vice President, Project Management and Clinical Operations, Europe. In her six years at PPD, Dr. Stansfield built her organization from 250 people to more than 1,750 people operating in 50 countries, while directing the successful execution of client projects and developing new business opportunities. Under Dr. Stansfield's management, the European operations achieved substantial increases in revenue, gross profit and operating margin.

Dr. Stansfield has also held senior management positions at Quintiles and Innovex, where she was responsible for business process improvement and managing full-service clinical research projects. Dr. Stansfield began her career in clinical research in various positions with the Wellcome Research Foundation, the Janssen Research Foundation, and Parke Davis.

Dr. Stansfield has a BSc in Physiology and Biochemistry from Nottingham University and a PhD in Neuropharmacology from Reading University.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements that are subject to risks and uncertainties relating to PRA International's future financial and business performance, as well as any other predictive statements that depend on future events or conditions, or that include words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "may," "will," "estimate" or similar expressions of futurity. You should not place undue reliance on any forward-looking statements, which represent the company's statements only as of the date of this news release and are not intended to give any assurance as to actual future events. Factors that might cause future events to differ include: operational and personnel challenges that could result from management changes; the ability to execute our strategy during management transitions; the ongoing need for early and late phase drug development services; project cancellations and timing issues; our ability to attract and retain qualified personnel; our ability to continue providing our services effectively, including the quality or accuracy of the data or reports provided and our ability to meet agreed-upon schedules; the ability and willingness of our clients to continue to spend on research and development at rates comparable to or greater than historical levels; trends or events affecting the CRO industry and the demand for CRO services; government regulation, including regulatory standards applicable to CRO services; evolving industry standards and technological changes; and general business and economic conditions. Events relating to PRA International could differ materially from those anticipated in these forward-looking statements. Although these statements are based upon assumptions company management believes to be reasonable based upon available information, they are subject to the foregoing risks and uncertainties as well as those described more fully in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our annual report on Form 10-K. This document can be accessed in the SEC's EDGAR database found at Please note that PRA International assumes no obligation to update any of the forward-looking statements in this release, except as required by applicable securities laws.

About PRA International

PRA International is one of the world's leading global clinical development organizations, with over 2,700 employees working from offices in North America, Europe, South America, Africa, Australia, and Asia. PRA delivers services to its clients through a unique approach called Project Assurance(R), which represents the company's commitment to reliable service delivery, program-level therapeutic expertise, easy, global access to knowledge, and involved senior management.

To learn more about PRA International, please visit or call our World Headquarters at +1 (703) 464-6300.

SOURCE PRA International
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. International community warns India on HIV situation
2. Key step forward on International Health Rules
3. ICMR along with other International Research organisation with drug development for Neglected Diseases
4. International Osteoporosis Research Centre To Be Started In India.
5. Indian hospitals require International Accreditation
6. International Conference On Malaria - Laveran To Genomics
7. Delhi To Host International Women’s Congress From Nov 2
8. International conference on Ayurveda to be held on Kerala
9. International Teleradiology: The Future Of Radiologic Diagnosis
10. John Mendelsohn M.D, chosen for an International Award
11. Thailand To Procure Botulism Antitoxin Internationally
Post Your Comments:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... of Australia,s successful biotechnology scientists, Dr ... company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is ... the ASX. Noxopharm is a clinic-ready company with its ... clinical study later this year. ... facing cancer patients - the ability of cancers to become resistant ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: